| Ticker: GENXY | 1, rue Robert & Sonia Delaunay | |
| Exchange: NASDAQ-National Market | Paris, Foreign 75011 | |
| Industry: Service | 3143565900 |
| Type of Shares: | American Depositary Receipts | Filing Date: | 5/13/96 | |
| U.S. Shares: | 5,400,000 | Offer Date: | 6/5/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $12.00 - $15.00 | |
| Primary Shares: | 5,400,000 | Offer Price: | $16.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.12 | |
| Offering Amount: | $72,900,000 | Selling: | $0.65 | |
| Expenses: | $1,767,400 | Reallowance: | $0.10 | |
| Shares Out After: | 19,304,100 |
| Manager | Tier | Phone |
| CS First Boston | Lead Manager | (212) 909-3312 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 576-3423 |
| Lehman Brothers Incorporated | Co-manager | (212) 640-6129 |
| Punk, Ziegel & Knoell | Co-manager | (212) 308-9494 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/96 | |||
| Revenue: | $5.42 | $1.60 | Assets: | $20.93 | |
| Net Income: | -$6.95 | -$3.51 | Liabilities: | $12.07 | |
| EPS: | -$1.58 | -$0.78 | Equity: | $8.86 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the analysis of the human genome to identify and patent genes and regulatory regions related to selected common diseases. The company plans to apply its genomics technology to discover drugs for such diseases. To date, other genomics companies have focused principally on either of two approaches: random sequencing to identify genes or gene fragments without regard to their role in the disease process; or positional cloning to identify disease-specific genes. The company's technological strategy is to apply large-scale, industrial techniques to these two conventional approaches and combine them with four new programs: high resolution mapping; 5 prime sequence and regulatory region identification; NetGene database and BioIntelligence analysis software; and functional polymorphism scanning (FPS). The company believes this integrated array of technologies will accelerate the identification of disease-related genes and regulatory regions. |
| Use of Proceeds |
| The proceeds from the offering will be used for capital expenditures, acquisition of equipment, research and development and for general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.